210 related articles for article (PubMed ID: 25985447)
1. Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines.
Junk S; Cario G; Wittner N; Stanulla M; Scherer R; Schlegelberger B; Schrappe M; von Neuhoff N; Lauten M
Klin Padiatr; 2015 May; 227(3):123-30. PubMed ID: 25985447
[TBL] [Abstract][Full Text] [Related]
2. A childhood acute lymphoblastic leukemia-specific lncRNA implicated in prednisolone resistance, cell proliferation, and migration.
Ouimet M; Drouin S; Lajoie M; Caron M; St-Onge P; Gioia R; Richer C; Sinnett D
Oncotarget; 2017 Jan; 8(5):7477-7488. PubMed ID: 27980230
[TBL] [Abstract][Full Text] [Related]
3. Altered expression of autophagy-related genes might contribute to glucocorticoid resistance in precursor B-cell-type acute lymphoblastic leukemia.
Sarang Z; Gyurina K; Scholtz B; Kiss C; Szegedi I
Eur J Haematol; 2016 Nov; 97(5):453-460. PubMed ID: 26947147
[TBL] [Abstract][Full Text] [Related]
4. Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance.
Han SS; Han S; Kamberos NL
Biochem Biophys Res Commun; 2014 Sep; 452(3):669-75. PubMed ID: 25193702
[TBL] [Abstract][Full Text] [Related]
5. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
6. NFkappaB modulators in a model of glucocorticoid resistant, childhood acute lymphoblastic leukemia.
Nicholson L; Hall AG; Redfern CP; Irving J
Leuk Res; 2010 Oct; 34(10):1366-73. PubMed ID: 20106524
[TBL] [Abstract][Full Text] [Related]
7. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
[TBL] [Abstract][Full Text] [Related]
8. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
[TBL] [Abstract][Full Text] [Related]
9. Acquisition of Fas resistance by Fas receptor mutation in a childhood B-precursor acute lymphoblastic leukemia cell line, MML-1.
Inaba H; Shimada K; Zhou YW; Ido M; Buck S; Yonehara S; Kaplan J; Komada Y
Int J Oncol; 2005 Aug; 27(2):573-9. PubMed ID: 16010441
[TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
[TBL] [Abstract][Full Text] [Related]
11. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
12. Targeting of the deubiquitinase USP9X attenuates B-cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance.
Zhou M; Wang T; Lai H; Zhao X; Yu Q; Zhou J; Yang Y
Biochem Biophys Res Commun; 2015 Apr; 459(2):333-339. PubMed ID: 25735983
[TBL] [Abstract][Full Text] [Related]
13. Role of microRNAs in glucocorticoid‑resistant B‑cell precursor acute lymphoblastic leukemia.
Sakurai N; Komada Y; Hanaki R; Morimoto M; Ito T; Nakato D; Hirayama M
Oncol Rep; 2019 Aug; 42(2):708-716. PubMed ID: 31233193
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
Lü S; Chen Z; Yang J; Chen L; Gong S; Zhou H; Guo L; Wang J
Exp Hematol; 2008 Oct; 36(10):1278-84. PubMed ID: 18562081
[TBL] [Abstract][Full Text] [Related]
15. Expression differences in TEL-AML1 fusion gene in leukemia glucocorticoid-sensitive and -resistant cell lines.
Wang XW; Xu YH
Genet Mol Res; 2015 Jul; 14(3):7883-93. PubMed ID: 26214469
[TBL] [Abstract][Full Text] [Related]
16. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
17. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
18. Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts.
Toscan CE; Rahimi M; Bhadbhade M; Pickford R; McAlpine SR; Lock RB
Org Biomol Chem; 2015 Jun; 13(22):6299-312. PubMed ID: 25967739
[TBL] [Abstract][Full Text] [Related]
19. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101.
Spijkers-Hagelstein JA; Schneider P; Pinhanços SM; Garrido Castro P; Pieters R; Stam RW
Eur J Cancer; 2014 Jun; 50(9):1665-74. PubMed ID: 24703900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
